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Role of secondary hyperparathyroidism in the genesis of hypertriglyc-
eridemia and VLDL receptor deficiency in chronic renal failure. Recent
studies have revealed marked down-regulation of hepatic lipase (HL),
lipoprotein lipase (LPL) and very low density lipoprotein-receptor
(VLDL-R) expressions in animals with chronic renal failure (CRF).
Acquired deficiency of these proteins, which together play an important
role in catabolism of triglyceride-rich lipoproteins, is involved in the
pathogenesis of CRF hypertriglyceridemia. Down-regulation of HL and
LPL expressions in CRF can be completely reversed by parathyroidectomy
(PTx), suggesting the role of excess parathormone (PTH). However, the
role of hyperparathyroidism in the pathogenesis of CRF-induced
VLDL-R deficiency has not been investigated before, and was studied
here. To this end, VLDL-R mRNA (Northern analysis) and VLDL-R
protein (Western analysis) of the fat pad and soleus muscle were
compared in CRF (5/6 nephrectomized) rats, CRF animals with PTx
(CRF-PTx) and sham-operated control animals. The CRF animals exhib-
ited marked hypertriglyceridemia coupled with significant reductions in
skeletal muscle and adipose tissue VLDL-R mRNA abundance and
protein mass. Parathyroidectomy resulted in a significant, but partial,
amelioration of CRF hypertriglyceridemia. However, in contrast to its
effect on HL and LPL expressions, PTx did not improve VLDL-R
expression, suggesting a PTH-independent mechanism for the latter
abnormality. The differential effect of PTx on HL and LPL on the one
hand and VLDL-R on the other can, in part, account for partial as
opposed to complete correction of the associated hypertriglyceridemia
with PTx in the CRF animals.
Very low density lipoprotein-receptor (VLDL-R) is a member
of the large low density lipoprotein (LDL) receptor family, which
despite substantial structural homology, is distinctly different
from the LDL receptor with respect to its ligand binding proper-
ties and tissue distribution. Accordingly, VLDL-R is primarily
expressed in skeletal muscle, heart and adipose tissue, and
specifically binds and internalizes Apo E-containing lipoproteins,
but does not bind LDL particles. In contrast, LDL receptor is
primarily expressed in the liver, adrenal glands and gonads and
binds lipoproteins through Apo-B100 in LDL particles or Apo E
in the intermediate density lipoproteins (IDL), b-migrating
VLDL and VLDL particles [1–7]. Based on its distinct ligand
binding affinity for triglyceride-rich VLDL particles and its pri-
mary distribution in myocytes and adipocytes (which use fatty
acids for energy metabolism), VLDL-R is thought to play an
important role in VLDL catabolism. In fact, we have found
marked down-regulations of VLDL-R in experimental chronic
renal failure (CRF) and nephrotic syndrome, conditions that are
associated with marked hypertriglyceridemia, elevated plasma
concentration and impaired clearance of VLDL [8, 9]. Very low
density lipoprotein-receptor is down-regulated in experimental
hypothyroidism, which is also associated with hypertriglyceride-
mia [10].
Recently, we have found that lipoprotein lipase (LPL) expres-
sion is markedly down-regulated by CRF [11], and that this
abnormality is completely reversed by parathyroidectomy (PTx)
[12]. In addition, Klin et al have shown that hepatic lipase gene
expression is depressed in rats with experimental CRF [13]. They
further demonstrated that CRF-associated down-regulation of
hepatic lipase is reversible by parathyroidectomy (PTx), suggest-
ing the causal role of excess parathormone (PTH) [13]. Interest-
ingly, normalization of LPL and hepatic lipase by PTx was
accompanied by partial as opposed to complete correction of the
associated hypertriglyceridemia in both studies [12, 13]. Based on
these observations, we asked if CRF-induced secondary hyper-
parathyroidism may contribute to the associated down-regulation
of VLDL receptor as well. We considered that if the answer to the
above question is negative then persistent VLDL-R deficiency
can, in part, account for the partial (as opposed to complete)
amelioration of CRF hypertriglyceridemia following PTx shown in




Male Sprague-Dawley rats weighing 225 to 250 g were pur-
chased from Harlan Sprague Dawley Inc. (Indianapolis, IN,
USA). They were housed in a climate-controlled, light-regulated
facility with 12-hour day (;500 lux) and 12-hour night (,5 lux)
cycles. The animals were fed regular rat chow (Purina Mills,
Brentwood, MO, USA) and water ad libitum. They were then
randomly assigned to the following groups:
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(1.) Chronic renal failure group (CRF). The animals assigned to
the CRF group were subjected to 5/6 nephrectomy by surgical
resection, using a dorsal incision as described previously [12].
2. Chronic renal failure-parathyroidectomy group (CRF-PTx).
Animals assigned to this group were first subjected to surgical
parathyroidectomy (PTx) without removing the thyroid tissue.
The procedure was carried out by electrocautery under a surgical
microscope as described by Ni et al [14]. The success of the
procedure was ascertained by demonstrating a fall in serum
calcium concentration by at least 2 mg/dl below the baseline
following PTx. The animals failing this test were excluded. In an
attempt to dissect the effect of PTx from that of the associated
hypocalcemia, the drinking water supply for these animals was
supplemented with calcium gluconate at a concentration of
50 g/liter. This intervention was sufficient to restore normocalce-
mia despite parathyroid ablation in these animals as demonstrated
by other investigators [14]. The animals were then allowed to
recover for one week after, which they were subjected to 5/6
nephrectomy as noted above.
(3.) Control group. The animals assigned to the control group
were subjected to sham operation and were provided free access
to food and water.
The study groups were observed for five weeks at which point
they were placed in metabolic cages for a 24-hour urine collection.
They were then sacrificed between the hours of 9 a.m. and 11 a.m.
by exsanguination using cardiac puncture. Soleus muscle and
supratesticular fat pad were harvested immediately, snap frozen in
liquid nitrogen and stored at 270°C until processed. All surgical
procedures were carried out under general anesthesia (pentobar-
bital, 50 mg/kg i.p.) while observing strict hemostasis and aseptic
techniques. Serum calcium concentration was measured by atomic
absorption spectrometry (Model 305; Perkin-Elmer Inc., Nor-
walk, CT, USA). Serum cholesterol, triglyceride, and creatinine
concentrations and urinary protein and creatinine contents were
determined using routine laboratory procedures. Arterial blood
pressure was determined by a tail sphygmomanometer (Harvard
Apparatus, South Natick, MA, USA).
Polymerase chain reaction
Polymerase chain reaction (PCR) was used to produce a partial
cDNA probe for rat VLDL-R using the following primers:
VLDL-R1 (nucleotide 361-383: 59 GATGGCAGTGACGAGAA-
GAACT 39) and VLDL-R2 (nucleotide 841-863: 59 CAA-
GAGACTCGTCTGATTGGTC 39) as described previously [8].
The nucleotide compositions of these primers were derived from
previously published VLDL-R sequence [10]. These primers were
used to amplify a 502 bp rat VLDL-R cDNA fragment. First
strand cDNA was synthesized from 1 mg rat heart poly(A1) RNA
(used as template) employing a cDNA cyclic kit (Invitrogene, San
Diego, CA, USA). The cDNA was then amplified by PCR in 50 ml
of a solution containing 10 mM Tris-HCl, 50 mM KCl, 1.5 mM
MgCl, 200 mM dNTP mixture, 1 U Taq polymerase and 1 mM of
each primer. The PCR amplification was carried out for 30 cycles.
Each cycle included the following steps: 94°C, 55°C and 72°C, one
minute each. The PCR products were separated on 1% agarose
gel, and the band corresponding to the 500 base pairs was cut,
isolated with a Gene-Clean TMII Kit (Qiagen Inc., Chatsworth,
CA, USA), then ligated to a PCR TMII vector using a TA cloning
kit (Invitrogene). Positive insert was sequenced by Sequenase
Version 2.0 Kit (United States Biochemical Co., Cleveland, OH,
USA) on double stranded DNA. To prepare the probe, approxi-
mately 0.5 Kb VLDL-R cDNA insert was excised by EcoRI from
the above clone.
RNA preparation and Northern blot analysis
The rats were killed between 9 and 11 a.m. The tissues were
removed immediately, frozen in liquid nitrogen and stored at
270°C until processed. Total RNA was prepared from 1 g of
tissue with RNAzol using the manufacture’s recommended pro-
cedure (Tel-Test Inc., Friendswood, TX, USA) as previously
described [8]. RNA concentration was determined from the
absorbance at 260 nm using a spectrophotometer (Gene-Quat;
Bio-Rad, Hercules, CA, USA). Twenty-five microgram aliquots of
total RNA were denatured in 2.2 M formaldehyde at 65°C for 15
minutes and run on 1.0% agrose/2.2 M formaldehyde gel at 46 V
for four hours. The separated RNA was transferred to the nylon
membrane (Zeta probe; Bio-Rad) by capillary blotting in 6 3 SSC
buffer overnight and immobilized by UV irradiation (Ultraviolet
Crosslinker; Fisher Scientific, Pittsburgh, PA, USA). The mem-
brane was incubated at 65°C in a solution containing 5 3 SSPE,
5 3 Denhard’s, 1% SDS and 100 mg/ml salmon sperm DNA for
two hours. The cDNA probe for rat glyceraldehyde phosphate
dehydrogenase (GAPDH) (1.3 Kb PstI fragment) was obtained
from American Type Culture Collection (ATCC, Rockville, MD,
USA). The cDNA probe for VLDL-R was prepared as described
above. The probes were labeled with [32P] dCTP (3000 Ci/mmol;
New England Nuclear Inc., Boston, MA, USA) by the random
primer method (Promega Inc., Madison, WI, USA). Hybridiza-
tion was carried out at 60°C in a prehybridization solution with 32P
labeled cDNA. The blots were washed twice in 2 3 SSPE/0.5%
SDS solution at room temperature, twice in 1 3 SSPE/0.5% SDS
solution at 37°C, and twice in 0.1 3 SSPE/0.5% SDS solution at
65°C, for 15 minutes each. The washed blots were exposed to
X-ray film (New England Nuclear Inc.) at 280°C for two to six
hours for GAPDH and two to three days for VLDL-R. The
autoradiographs were scanned with a laser densitometer (Molec-
ular Dynamics, Sunnyvale, CA, USA) to determine relative
mRNA levels. The values obtained for constitutively expressed
GAPDH gene were used as an internal control.
Monoclonal antibody production
The hybridoma cell line, IgG-6A6, producing mouse monoclo-
nal antibody recognizing the cytoplasmic domain of the VLDL-R
from various tissues and species was purchased from ATCC. The
hybridoma was grown in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco BRL Products, Gaithersburg, MD, USA) with
10% fetal calf serum (FCS). The cells were then subcultured and
allowed to overgrow until cell death occurred. The supernatant
containing the antibody was harvested and stored.
Western blot analysis
Muscle and fat cell plasma membranes were prepared as
follows: frozen rat tissues were homogenized in 20 mM Tris-HCl
(pH 7.5) containing 2 mM MgCl2, 0.2 M sucrose, 5 mM phenyl-
methylsulfonyl fluoride, 5 mg/ml leupeptin, 10 mg/ml aprotinin and
3 mg/ml pepstatin A. The crude extracts were centrifuged at
3000 3 g for 10 minutes at 4°C. The supernatant was then
centrifuged at 35,000 3 g for 30 minutes. The crude membrane
preparations were washed with the above buffer and centrifuged
at 35,000 3 g for 45 minutes at 4°C. Protein concentration was
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determined using a Bio-Rad Kit (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). One-hundred microgram protein aliquots
were size-fractionated on 4 to 12% Tris-glycine gel (Novex, San
Diego, CA, USA) at 120 V for two hours. After electrophoresis,
proteins were transferred to Hybond-ECL membrane (Amersham
Life Science Inc., Arlington Heights, IL, USA). The membrane
was incubated for one hour in buffer A (1 3 PBS, 0.1% Tween-20
and 8% nonfat milk) and then overnight in the same buffer to
which 1:10 dilution of the above antibody preparation were added.
The membrane was washed once for 15 minutes and then twice
for five minutes in 1 3 PBS, 0.1% Tween-20 prior to a one hour
incubation in buffer A to which diluted (1:1000) horseradish
peroxidase-linked sheep anti-mouse IgG (Amersham) was added.
The washes were repeated before the membranes were developed
with chemiluminescent agents (ECL; Amersham) and subjected
to luminography for one hour.
Data analysis
Analysis of variance (ANOVA) and Duncan’s multiple range
test were performed in evaluation of the data. P values equal to or




As expected, the CRF animals showed a significant fall in
creatinine clearance and a significant rise in arterial blood pres-
sure. This was associated with a marked elevation of serum
triglyceride concentration and modest increase in serum choles-
terol level. Parathyroidectomy (PTx) led to a significant fall in
serum triglyceride concentration from the high levels seen in CRF
animals with intact parathyroid glands. However, PTx did not
lower triglyceride level to the normal value. Serum calcium
concentration in the PTx animals prior to calcium gluconate
supplementation was significantly below that of the control group
(serum Ca 5 5.38 6 0.5 mg/dl vs. 9.2 6 0.2 mg/dl in the controls,
P , 0.01). However, with calcium supplementation, serum cal-
cium in the CRF-PTx group rose to a level (9.7 6 0.4 mg/dl),
which was comparable to those seen in the CRF group (9.1 6 0.3
mg/dl) and the normal control group (9.6 6 0.15 mg/dl). Data are
shown in Table 1.
Very low density lipoprotein-receptor mRNA abundance
Compared to the control group, the CRF animals showed a
marked reduction in the skeletal muscle VLDL-R mRNA abun-
dance consistent with our earlier studies [8]. In addition, fat tissue
VLDL-R mRNA abundance (not studied before) was significantly
reduced in the CRF animals. Impaired VLDL-R mRNA abun-
dance in the CRF animals did not improve with PTx, contrasting
with the results reported for lipoprotein lipase [12] and hepatic
lipase [13] whose expressions markedly improved with PTx in the
CRF animals. Data are depicted in Figures 1 and 2.
Very low density lipoprotein-receptor protein mass
As reported previously [8], VLDL-R protein abundance in the
plasma membrane fraction of the skeletal muscle tissue was
greatly reduced in the CRF animals. In addition, the study
revealed a marked reduction in adipose tissue VLDL-R protein
that had not been studied previously. As with the mRNA abun-
dance, PTx failed to improve the CRF-associated reduction of
VLDL-R protein in fat and skeletal muscle. This contrasts the
effects of PTx on LPL and hepatic lipase, enzymes that play an
important role in triglyceride metabolism (Figs. 3, 4) [12, 13].
DISCUSSION
The present study confirmed the earlier observation reported
by our laboratory that CRF leads to marked down-regulation of
skeletal muscle VLDL-R mRNA and protein mass. In addition,
the present study revealed, for the first time, that VLDL-R
deficiency in CRF is not confined to the muscle tissue that uses
VLDL for energy production, but it also affects adipose tissue,
Fig. 1. A representative autoradiograph of the
Northern blots of very low density lipoprotein
(VLDL) receptor mRNA and the corresponding
GAPDH mRNA of the adipose tissue and skeletal
muscle of the sham-operated control (NL), CRF
rats with intact parathyroid glands (CRF) and
CRF rats with surgical parathyroidectomy (CRF-
PTx).
Table 1. Serum concentrations of total cholesterol, triglycerides and
creatinine, systolic blood pressure (BP), creatinine clearance (CCr), and
24-hour urine protein excretion in the normal control (NL) animals,
chronic renal failure rats with intact parathyroid glands (CRF), and






55.6 6 3.5 132.4 6 21.8 154.8 6 19.5 , 0.003
Triglyceride
mg/dl
51.4 6 4.9 152.7 6 23.5 108.3 6 13.2a , 0.001
Creatinine
mg/dl
0.43 6 0.04 0.99 6 0.18 0.92 6 0.05 ,0.003
CCr ml/min 1.98 6 0.2 0.67 6 0.2 0.74 6 0.1 , 0.003
Systolic BP
mm Hg
125.7 6 1.6 153.8 6 1.8 139.3 6 1.5a , 0.05
Urine protein
mg/24 hr
10.1 6 1.4 44.6 6 2.8 42.2 6 4.1 , 0.003
a P , 0.05 vs. CRF group (Duncan’s multiple range test)
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which serves as an energy storage facility. Thus, the effect of CRF
on VLDL-R expression is diffuse and not tissue specific. Similar
diffuse and depressive effects were previously noted with LPL in
all tested tissues in the CRF animals [11]. This effect of CRF is
distinct from those of the physiological regulators such as thyroid
hormone, exercise, feeding and fasting states that modulate LPL
expression in the fat and muscle tissues in the opposite directions.
Thus, the effect of uremia on expression of these lipid regulatory
factors represents a pathophysiological as opposed to a physio-
logical phenomenon.
In contrast to its effect on LPL and hepatic lipase expression,
PTx did not improve VLDL-R expression in the CRF animals.
Thus, CRF-induced down-regulation of VLDL-R expression must
involve a different mechanism(s) than that of LPL and HL
expressions. Given the distinct structural and functional differ-
ences of VLDL-R from HL and LPL, it is not surprising that their
dysregulation in CRF may involve different mechanisms.
Interestingly, while improving hypertriglyceridemia, PTx did
not restore normal triglyceride concentration in the CRF animals.
This partial, but not complete, amelioration of CRF-hypertriglyc-
eridemia with PTx can be, in part, explained by its divergent action
on HL and LPL on the one hand and VLDL-R on the other.
Accordingly, correction of HL and LPL deficiencies by PTx can
account for the partial reduction in plasma triglycerides in CRF-
PTx animals. However, persistent VLDL-R deficiency in CRF-
PTx animals can, in part, account for the residual hypertriglycer-
idemia in these animals. The authors wish to acknowledge that the
present study of VLDL-R and earlier studies of LPL [12] and
hepatic lipase [13] have specifically dealt with the effects of excess
PTH on the gene expressions of three important proteins involved
in VLDL and triglyceride catabolism. Consequently, several other
important questions such as the possible effects of excess PTH on
triglyceride and VLDL synthesis, VLDL—VLDL-R affinity and
lipoprotein composition, have not been addressed in these studies
and await future investigations.
According to a recent study, CRF is associated with depressed
expression of receptors for parathormone (PTH-PTHrP recep-
tor), angiotensin II (AT1 receptor), vasopressin (V1a receptor),
which act through the G-protein-adenylcyclase-cAMP-dependent
calcium signaling pathway [15]. The down-regulation of these
receptors and the associated impaired calcium signaling in re-
sponse to their respective agonists improved by either PTx or
calcium channel blockade, which reversed the abnormal elevation
of cytosolic [Ca21] in the CRF animals. Thus, by raising the
cytosolic [Ca21]i, excess PTH plays a major role in down-regula-
tion of several hormone receptors [15] and enzymes [12, 13] in
CRF. However, based on the present data, excess PTH does not
appear to be involved in down-regulation of VLDL-R in CRF.
Further studies are required to discern the mechanism(s) respon-
sible for depressed VLDL-R expression in chronic renal insuffi-
ciency.
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Fig. 2. Comparison of adipose tissue and skeletal muscle very low density
lipoprotein-receptor (VLDL-R)/GAPDH mRNA in the normal control
group (NL, N 5 6), chronic renal failure (CRF) rats with intact
parathyroid glands (CRF, N 5 6) and CRF rats with surgical parathy-
roidectomy (CRF-PTx, N 5 6). Data are given as mean 6 SEM. P , 0.01
versus NL group
Fig. 3. Representative Western blot of very low density lipoprotein
(VLDL) receptor protein in the adipose tissue and skeletal muscle of the
sham-operated control (NL), chronic renal failure rats with intact
parathyroid glands (CRF), and CRF rats with surgical parathyroidec-
tomy (CRF-PTx).
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